Evidence map›Paper›PMID 41469568›Full record

ArticleBMC cardiovascular disorders2025

Nationwide patterns of cardiac-related mortality in amyloidosis cases: an epidemiologic study.

Abdalhakim Shubietah, Diana Owda, Mohamed Saad Rakab, Yazan Dawoud, Ahmed Khraiwesh, Mohamed S Elgendy, Mohammed Tareq Mutar, Ahmed Emara, Ali Saad Al-Shammari, Ameer Awashra and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Abdalhakim ShubietahDepartment of Medicine, Advocate Illinois Masonic Medical Center, Chicago, IL, USA.
Diana OwdaDepartment of Medicine, An-Najah National University, Nablus, West Bank, Palestine.
Mohamed Saad RakabFaculty of Medicine, Mansoura University, Mansoura, Egypt.
Yazan DawoudDepartment of Medicine, An-Najah National University, Nablus, West Bank, Palestine.
Ahmed KhraiweshDepartment of Medicine, An-Najah National University, Nablus, West Bank, Palestine.
Mohamed S ElgendyFaculty of Medicine, Tanta University, Tanta, Egypt.ORCID 0000-0003-3080-2875
Mohammed Tareq MutarCollege of Medicine, University of Baghdad, Baghdad, Iraq.
Ahmed EmaraFaculty of Medicine, Al-Azhar University, Cairo, Egypt.
Ali Saad Al-ShammariCollege of Medicine, University of Baghdad, Baghdad, Iraq.
Ameer AwashraDepartment of Medicine, An-Najah National University, Nablus, West Bank, Palestine. ameer.awashra7@gmail.com.
Mohammed AbuBahaDepartment of Medicine, An-Najah National University, Nablus, West Bank, Palestine.
Zaina NazzalResearch and Teaching Assistant, An-Najah National University, BSc (Anesthesia & Resuscitation Technology), Nablus, Palestine.
Bandar AlyamiDepartment of Interventional Cardiology, West Virginia University, Morgantown, WV, USA.
Ramesh DaggubatiDepartment of Interventional Cardiology, West Virginia University, Morgantown, WV, USA.
Yasar SattarDepartment of Interventional Cardiology, Tidal Health Nanticoke, Seaford, DE, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCardiac amyloidosis is frequently overlooked, leading to delayed diagnosis and underestimation of its true impact on cardiac mortality.

methodsUsing CDC WONDER (1999-2020), we identified U.S. decedents aged ≥ 25 years with amyloidosis (ICD-10 E85) as the underlying cause of death and at least one cardiac-related condition as a contributing cause. Age-adjusted mortality rates (AAMRs) per 100,000 population were calculated, and trends were analyzed using Joinpoint regression and autoregressive integrated moving average (ARIMA) forecasting through 2040.

resultsAmong 16,673 deaths, the AAMR rose from 0.261 in 1999 to 0.608 in 2020, with inflection points in 2012 and 2017 and an overall annual increase of 3.96%. Mortality was higher in men (0.537 vs. 0.210) and Black individuals (0.83 vs. 0.32), with a sharp post-2017 rise, especially among Black decedents. Geographic disparities were also observed, with the highest rates in the Northeast and urban areas. Most deaths occurred in hospitals (43.2%) or at home (31.4%), and mortality rates peaked in those aged 85 and older. Forecasting models project continued increases in AAMR through 2040, reaching approximately 2.0 overall, with especially elevated rates among Black (≈ 5.9) and male (≈ 3.8) decedents.

conclusionCardiac mortality in amyloidosis has risen sharply since 2017, likely driven by improved ATTR-CM detection through non-biopsy imaging and guideline adoption. Disparities by sex, race, and geography persist, reflecting uneven diagnostic capacity concentrated in urban and Northeastern centers. Forecasts project continued increases, particularly among Black and male individuals, underscoring the need for more equitable access to diagnosis and treatment.

Indexed as

AmyloidosisCardiomyopathiesAdultAgedAged, 80 and overAge DistributionAge FactorsCause of DeathDatabases, FactualFemaleHealth Status DisparitiesHumansMaleMiddle AgedPrognosisRisk AssessmentARIMA forecastingCardiac amyloidosis mortalityHealth disparitiesTemporal trends

Identifiers

PMID41469568
PMCPMC12754875

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.